Newbury Pharmaceuticals is strengthening its portfolio with Buspirone tablets
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2023-02-02 07:45:00
Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Buspirone tablets.
“Buspirone is a medication for anxiety (anxiolytic) that works by affecting certain natural substances in the brain (neurotransmitters). With the addition of Buspirone we have also secured a new strategic partnership which can be used to source additional new products.” says Mr Lars Minor CEO of Newbury
Regulatory filling will take place in the near time, and we aim to launch this medicine in Sweden and Finland where the total annual value of the market is estimated to be 1,5 MEUR according to DLMI Nordic Pharma Insights.
Newbury currently has more than 30 products in its portfolio and the first launches took place in 2022 with additional launches planned in the years ahead.